LexDanaLexDanabeta
Inventor

Gregory Alan Lazar

Inventor
Arcadia, CA, US

Overview

82→
Patents
2007–2021
Patent span
Human necessities
Primary field (CPC A)

Patents· 82 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

C07Kprimary
C07KPeptides32%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations24%
A61KPreparations for medical, dental or toiletry purposes24%
G16BBioinformatics, i.e. information and communication technology [ict] specially adapted for genetic or protein-related data processing in computational molecular biology4%
C12PFermentation or enzyme-using processes to synthesise a desired chemical compound or composition or to separate optical isomers from a racemic mixture3%
G16CComputational chemistry3%
Y02ATechnologies for adaptation to climate change3%
C12NMicroorganisms or enzymes2%
C07HSugars1%
C40BCombinatorial chemistry1%
PatentTitleYear
11,066,657Methods and compositions for stabilizing trans-splicing intein modified proteases202111,046,776Multivalent and multiepitopic antibodies having agonistic activity and methods of use202111,008,403Anti-transferrin receptor / anti-BACE1 multispecific antibodies and methods of use202110,808,036Anti-transferrin receptor antibodies and methods of use202010,709,766Fusion proteins202010,626,182Optimized antibodies that target CD19202010,584,176Fc variants with increased affinity for FcgRIIc202010,508,151Anti-transferrin receptor antibodies and methods of use201910,336,818Fc variants with altered binding to FcRn201910,183,999Optimized Fc variants and methods for their generation201910,184,000Optimized Fc variants and methods for their generation201910,155,800CTLA4-Ig immunoadhesins201810,118,959Anti-glypican-3 antibody201810,113,001Fc variants with increased affinity for FcyRIIc20189,914,778'Methods and compositions for inhibiting CD32B expressing cells'20189,902,773'Methods and compositions for inhibiting CD32b expressing cells'20189,855,318'Fusion proteins'20189,803,020'Optimized antibodies that target CD19'20179,803,023'Fc variants with altered binding to FcRn'20179,714,282'Optimized Fc variants and methods for their generation'20179,708,406'Anti-transferrin receptor antibodies and methods of use'20179,663,582'Optimized Fc variants'20179,657,106'Optimized Fc variants'20179,605,061'Antibodies with modified isoelectric points'20179,574,006'Optimized anti-CD30 antibodies'20179,493,578'Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens'20169,475,881'Antibody variants with enhanced complement activity'20169,394,366'Methods and compositions for inhibiting CD32B expressing cells'20169,371,397'CTLA4-Ig immunoadhesins'20169,353,187'Optimized FC variants and methods for their generation'20169,260,523'Methods and compositions for inhibiting CD32b expressing cells'20169,200,079'Fc variants with altered binding to FcRn'20159,193,798'Optimized Fc variants and methods for their generation'20159,102,739'Anti-glypican-3 antibody'20159,079,960'Methods and compositions for inhibiting CD32B expressing cells'20159,051,373'Optimized Fc variants'20159,040,041'Modified FC molecules'20159,040,042'Optimized antibodies that target HM1.24'20158,937,158'Fc variants with increased affinity for FcγRIIc'20158,883,973'Fc variants with altered binding to FcRn'20148,883,147'Immunoglobulins insertions, deletions, and substitutions'20148,858,937'Optimized Fc variants and methods for their generation'20148,852,586'Fc variants with altered binding to FcRn'20148,809,503'Optimized Fc variants and methods for their generation'20148,802,820'Fc variants with altered binding to FcRn'20148,802,823'Optimized Fc variants'20148,753,628'Optimized Fc variants'20148,753,629'Optimized Fc variants'20148,734,791'Optimized fc variants and methods for their generation'20148,735,545'Fc variants having increased affinity for fcyrllc'20148,735,547'Optimized Fc Variants'20148,637,641'Antibodies with modified isoelectric points'20148,629,113'CTLA4-Ig immunoadhesins'20148,551,485'Anti-CD40 antibodies and methods of inhibiting proliferation of CD40 expressing cells'20138,546,543'Fc variants that extend antibody half-life'20138,524,867'Optimized antibodies that target CD19'20138,399,618'Immunoglobulin insertions, deletions, and substitutions'20138,394,925'Fc variants with altered binding to FcRn'20138,394,374'Optimized antibodies that target HM1.24'20138,388,955'Fc variants'20138,383,109'Optimized Fc variants and methods for their generation'20138,367,805'Fc variants with altered binding to FcRn'20138,362,210'Antibody variants with enhanced complement activity'20138,338,574'FC variants with altered binding to FCRN'20128,329,867'CTLA4-Ig immunoadhesins'20128,324,351'Fc variants with altered binding to FcRn'20128,318,907'Fc variants with altered binding to FcRn'20128,188,231'Optimized FC variants'20128,124,731'Optimized Fc variants and methods for their generation'20128,101,720'Immunoglobulin insertions, deletions and substitutions'20128,093,357'Optimized Fc variants and methods for their generation'20128,093,359'Optimized Fc variants and methods for their generation'20128,088,376'Fc variants with altered binding to FcRn'20128,084,582'Optimized anti-CD20 monoclonal antibodies having Fc variants'20118,063,187'Methods and compositions for inhibiting CD32B expressing cells'20118,039,592'Optimized Fc variants and methods for their generation'20117,973,136'Optimized anti-CD30 antibodies'20117,930,107'Methods of generating variant proteins with increased host string content'20117,662,925'Optimized Fc variants and methods for their generation'20107,657,380'Methods of generating variant antibodies with increased host string content'20107,317,091'Optimized Fc variants'20087,276,585'Immunoglobulin variants outside the Fc region'2007

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

2007–2020Patents assigned to XENCOR INC (74)· patent assignee history
2007–2018Based in Los Angeles, CA, US· patent location history
2011–2017Patents assigned to KARKI SHER BAHADUR (35)· patent assignee history
2011–2017Patents assigned to LAZAR GREGORY ALAN (35)· patent assignee history
2011–2017Patents assigned to DESJARLAIS JOHN R (27)· patent assignee history
2011–2015Patents assigned to VAFA OMID (15)· patent assignee history
2011–2020Based in Arcadia, CA, US· patent location history
2011–2014Based in Alhambra, CA, US· patent location history
2014–2019Based in Indianapolis, IN, US· patent location history
2016–2020Based in Pacifica, CA, US· patent location history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
XENCOR INC742007–2020
KARKI SHER BAHADUR352011–2017
LAZAR GREGORY ALANself352011–2017
DESJARLAIS JOHN R272011–2017
VAFA OMID152011–2015
Locations
LocationPatentsSpan
Arcadia, California, US312011–2020
Indianapolis, IN, US142014–2019
Los Angeles, California, US132007–2018
Pacifica, California, US92016–2020
Alhambra, California, US72011–2014